Literature DB >> 1936065

Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses.

G Caillé1, S Boucher, J Spénard, Z Lakhani, A Russell, J Thiffault, M G Grace.   

Abstract

In young healthy volunteers diltiazem does not have linear kinetics between single and multiple doses. Elimination half-life increases and gives AUC's and Cmax higher than those predicted from single dose data. Kinetics of diltiazem were assessed in 16 healthy elderly after a single 60 mg dose and in 24 healthy elderly after 60 mg every 8 h for 7 days. Thirteen participants completed both studies. Elimination half-life, AUC0-24, AUC0-infinity, and Cmax were (mean +/- SE) 7.4 (1.2) h, 349 (34) ng/ml.h, 392 (44) ng/ml.h, and 43 (5) ng/ml respectively after a single dose. After multiple doses elimination half-life, AUC0-48, AUC0-infinity, Cmax and Cmin were respectively 5.7 (0.3) h, 974 (107) ng/ml.h, 1022 (108) ng/ml.h, 102 (7) ng/ml and 43 (5) ng/ml. Exploratory statistics on the 13 volunteers common to both studies showed that the ratio of AUC desacetyl-diltiazem (DAD)/AUC diltiazem rose between single and multiple doses while elimination half-life of both diltiazem and N-desmethyl-diltiazem (MA), tmax, and AUC MA/AUC diltiazem were not affected. The conclusion of this study is that elimination half-life of diltiazem does not increase in elderly between single and multiple doses, possibly due to an increased biotransformation into DAD.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1936065     DOI: 10.1007/BF03189878

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  22 in total

1.  Pharmacokinetics of oral diltiazem and five of its metabolites in patients with chronic renal failure.

Authors:  M Tawashi; J Marc-Aurèle; D Bichet; J Spénard; L Larivière; D Plante; G Caillé
Journal:  Biopharm Drug Dispos       Date:  1991-03       Impact factor: 1.627

2.  Pharmacokinetics of slow-release diltiazem and its effect on atrioventricular conduction in healthy volunteers.

Authors:  A Gordin; P Pohto; S Sundberg; S Nykänen; H Haataja; P Männistö
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Pharmacokinetics of diltiazem after intravenous and oral administration.

Authors:  P Hermann; S D Rodger; G Remones; J P Thenot; D R London; P L Morselli
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Assay of diltiazem and deacetyldiltiazem by capillary gas chromatography.

Authors:  O Grech-Belanger; E Leboeuf; S Langlois
Journal:  J Chromatogr       Date:  1987-06-05

5.  N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives.

Authors:  S C Montamat; D R Abernethy
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

6.  Pharmacokinetics of diltiazem in severe renal failure.

Authors:  N Pozet; J L Brazier; A H Aïssa; D Khenfer; G Faucon; E Apoil; J Traeger
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Pharmacokinetics and absolute bioavailability of diltiazem in humans.

Authors:  H R Ochs; M Knüchel
Journal:  Klin Wochenschr       Date:  1984-04-02

8.  Pharmacokinetics of diltiazem in selected animal species and human beings.

Authors:  R W Piepho; D C Bloedow; J P Lacz; D J Runser; D C Dimmit; R K Browne
Journal:  Am J Cardiol       Date:  1982-02-18       Impact factor: 2.778

9.  Pharmacokinetics and metabolism of diltiazem in man.

Authors:  V Rovei; R Gomeni; M Mitchard; J Larribaud; C Blatrix; J J Thebault; P L Morselli
Journal:  Acta Cardiol       Date:  1980       Impact factor: 1.718

10.  Responses to intravenous and oral diltiazem in elderly and younger patients with systemic hypertension.

Authors:  J B Schwartz; D R Abernethy
Journal:  Am J Cardiol       Date:  1987-05-01       Impact factor: 2.778

View more
  4 in total

Review 1.  Bioequivalence of controlled-release calcium antagonists.

Authors:  R Schall; F R Müller; F O Müller; H G Luus
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

2.  Pharmacokinetics and hypotensive effect of deacetyl N-monodesmethyl diltiazem (M2) in rabbits after a single intravenous administration.

Authors:  P K Yeung; J D Feng; S J Buckley
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.441

Review 3.  Diltiazem. A review of its pharmacology and therapeutic use in older patients.

Authors:  A Markham; R N Brogden
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

4.  Pharmacokinetics and metabolism of diltiazem in healthy males and females following a single oral dose.

Authors:  P K Yeung; C Prescott; C Haddad; T J Montague; C McGregor; M A Quilliam; M Xei; R Li; P Farmer; G A Klassen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Apr-Jun       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.